Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05060341

Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia

This study is a long-term follow-up study for patients who have been administered AAV2hAQP1 in the Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity in Subjects with Radiation Induced Parotid Gland Hypofunction and Xerostomia

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Radiation-Induced Xerostomia

Age range

18 year–81 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Health Sciences North - Northeast Cancer Center, Greater Sudbury, Ontario, Canada

Loading trial locations.

About this study

This clinical trial is designed to assess the long-term safety and activity of intra-parotid administration of AAV2hAQP1 in subjects with radiation-induced parotid salivary hypofunction and xerostomia.

After completion of their Month 12 Follow-Up visit in Study MGT016, subjects will be invited to enroll in this 4-year follow-up study during which they will be assessed for up to 60 months following study drug administration. This follow-up trial is a non-interventional study designed to collect data on longer-term safety and activity at 18, 24, 36, 48, and 60 months following study drug administration.

Over the course of the study, subjects will undergo physical and oral examinations; vital sign measurements; weight measurements; AE assessments; concurrent medication assessments; sample blood collection for hematology and chemistry; urinalysis; ear, nose, and throat (ENT) screening for malignancy; imaging assessments (if indicated); salivary flow assessments; and questionnaire assessments.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are willing and able to provide informed consent
  • Received AAV2hAQP1 administered via Stensen's duct to a single or both parotid glands in the prior open-label, Phase 1, dose-escalation study (Study MGT016)
  • Are willing and able to adhere to the protocol and long-term follow-up

Exclusion criteria

  • Subjects unwilling or unable to meet with the requirements of the study will be excluded

Treatment and study plan

Primary outcomes

  1. • Incidence of AEs, treatment-emergent adverse events (TEAEs), and SAEs

    Time frame: 4 years

    Safety

Secondary outcomes

  1. Changes in saliva flow compared to baseline.

    Time frame: 4 years

    Changes in unstimulated and stimulated salivary output (mL/minute) of the treated parotid gland and/or whole saliva output as compared to baseline.

  2. Changes in the McMaster Global Rate of Change relative to Baseline

    Time frame: 4 years

    This first part of this questionnaire asks the patient to evaluate their Dry Mouth relative to before treatment as better, worse, or the same. If better or worse, the patient is asked to rate the magnitude of change, on a scale of 1-7, with a higher score being a better outcome.

    This first part of this questionnaire asks the patient to evaluate how limited they are in daily activities due to dry mouth, relative to before treatment as better, worse, or the same. If better or worse, the patient is asked to rate the magnitude of change, on a scale of 1-7, with a higher score being a better outcome.

  3. Changes in the Xerostomia Questionnaire relative to Baseline

    Time frame: 4 years

    The XQ is a series of 8 questions designed to assess the degree of xerostomia symptoms. Each question is a scale of 1-10, with high values indicating worse xerostomia.

  4. Changes in the MD Anderson Symptom Inventory - Head and Neck

    Time frame: 4 years

    The MDASI-HN is a questionnaire consisting of 28 questions designed to assess the degree of xerostomia symptoms. Each question is a scale of 1-10, with high values indicating worse xerostomia.

Sponsors and collaborators

Lead sponsor

MeiraGTx, LLC

Industry

Registry information

Official study title

Long-Term Follow-Up Study of Participants Enrolled in the MGT016 Phase 1, Open-Label, Dose-Escalation Study of AAV2hAQP1 for Radiation-Induced Parotid Gland Hypofunction and Xerostomia

Important dates

Study start
2020
Primary completion
2027
Study completion
2027
First posted
Sep 29, 2021
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.